New warnings will be added to the labels of gonadotropin-releasing hormone (GnRH) agonists, a class of drugs primarily used to treat men with prostate cancer, the FDA announced last week.
prostate cancer in some men, suggested new guidelines from the American Cancer Society. ... Men with multiple family members diagnosed with prostate cancer before age 65 should receive this information beginning at age 40.
A total of 4,921 men died, 1,049 of causes related to prostate cancer. ... or prostate cancer-specific mortality (HR, 1.03; 95% CI, 0.89 to 1.19).
To develop an evidence-based guideline on prostate cancer chemoprevention, the American Society of Clinical Oncology and the American Urological Association did a systematic literature review of 15 randomized clinical trials ... The committee identified
Researchers noted that men undergoing either prostate cancer treatment had declines in all functional outcomes throughout early, intermediate and long-term follow-up. ... They wrote, “Considering the often long duration of survival after treatment for
The paper was published online in the Feb. 1 Circulation. ADT is widely used for prostate cancer. ... It's a mainstay for overt metastatic disease, and the standard of care for high-risk prostate cancer when combined with external-beam radiation therapy.
https://acpinternist.org/weekly/archives/2011/09/27/4.htm. Researchers have developed a new model to predict the risk of erectile dysfunction for men undergoing prostate cancer treatment. ... Researchers have developed a new model to predict the risk of
The Reduction by Dutasteride of Prostate Cancer Events (REDUCE) study was done in collaboration with the drug's maker, GlaxoSmithKline. ... In the placebo group, men with prostate cancer were withdrawn from the study, so during years 3 and 4, there were
One physician describes how his informed consent process was the deciding factor in a missed case of prostate cancer, and outlines how any physician can accomplish it. ... In 1990, Dr. Gottesman was sued for late diagnosis of a patient's prostate cancer.
two more years of follow-up results in the European Randomized Study of Screening for Prostate Cancer. ... We are left with an unsatisfactory situation, in which many practitioners will think there are insufficient data to recommend abandoning PSA